Sunovion Pharmaceuticals launched its Lonhala Magnair drug in the U.S. for the long-term maintenance treatment of airflow obstruction in people with chronic obstructive pulmonary disease, the company reported today.
Sunovion touts its drug as the first nebulized long-acting muscarinic antagonist approved to treat COPD in the U.S. The product is delivered using the Magnair nebulizer system, which is designed to administer medication in two to three minutes.
Get the full story at our sister site, Drug Delivery Business News.
The post Sunovion launches inhaled COPD therapy in U.S. appeared first on MassDevice.
from MassDevice https://ift.tt/2q1W5qq
Cap comentari:
Publica un comentari a l'entrada